Toleris Biotherapeutics GmbH products

AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process observed in pregnancy that protects the embryo from the maternal immune system. By leveraging optimized soluble versions of the non-classical MHC Ib molecule HLA-G, AIM Biologicals can accumulate in lymph nodes to induce regulatory CD8+ T cells that protect tissues presenting autoantigens attacked in autoimmune diseases. This targeted approach contrasts with traditional immunosuppressants that broadly inhibit immune functions, risking opportunistic infections. AIM Biologicals focus on directing tolerance towards organ-specific autoantigens, thereby avoiding interference with the beneficial immune responses to pathogens. They are engineered to exploit natural immune tolerance mechanisms to stop autoimmune disease progression while minimizing side effects and maximizing therapeutic potential. Studies in model systems have shown promising results in inducing antigen-specific tolerance and reducing autoimmune symptoms.